Back to Search
Start Over
Cost-effectiveness of pre-exposure prophylaxis for HIV: a review.
- Source :
-
Current opinion in HIV and AIDS [Curr Opin HIV AIDS] 2012 Nov; Vol. 7 (6), pp. 587-92. - Publication Year :
- 2012
-
Abstract
- Purpose of Review: The US Food and Drug Administration (FDA) recently approved the use of tenofovir-emtricitabine for pre-exposure prophylaxis (PrEP) for HIV prevention. PrEP is also being investigated in clinical trials as a component of HIV prevention in resource-limited settings. Cost-effectiveness models are useful in identifying health programs with the greatest societal value and projecting long-term program impacts. This review examines six recent studies of the cost-effectiveness of PrEP for preventing HIV transmission in the USA and South Africa.<br />Recent Findings: Studies used both individual-level and population-level transmission models. PrEP was found to be a cost-effective HIV-prevention intervention in high-risk MSM with HIV incidence at least 2% in the USA (<US$100 000 per quality-adjusted life year) and in young women in South Africa (cost per life year <GDP per capita). Results were sensitive to the cost and efficacy of PrEP and to assumptions about HIV testing and access to treatment in the absence of PrEP.<br />Summary: Future cost effectiveness studies should consider PrEP implementation issues (uptake in high-risk versus low-risk groups, duration on PrEP, adherence), budget impact, and the role of PrEP as part of combination HIV-prevention strategies including expanded testing and treatment access.
Details
- Language :
- English
- ISSN :
- 1746-6318
- Volume :
- 7
- Issue :
- 6
- Database :
- MEDLINE
- Journal :
- Current opinion in HIV and AIDS
- Publication Type :
- Academic Journal
- Accession number :
- 23076124
- Full Text :
- https://doi.org/10.1097/COH.0b013e3283582c8b